Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Nuijten

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
Clinicoeconomics and Outcomes Research : CEOR|December 19, 2013
Health economic evidence of 5% lidocaine medicated plaster in post-herpetic neuralgiaHiltrud Liedgens, Marko Obradovic, Mark Nuijten
Clinical Drug Investigation|January 14, 2010
Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysisMark Ritchie, Hiltrud Liedgens, Mark Nuijten
Journal of Medical Economics|October 9, 2009
Cost effectiveness of palivizumab for RSV prevention in high-risk children in the NetherlandsMark Nuijten, Maximilian Lebmeier, Wolfgang Wittenberg
Journal of Medical Economics|March 25, 2014
The application of economics concepts to stratified medicine--use of health economics data to support market access for stratified medicine interventionsHans-Joerg Fugel, Mark Nuijten, Eric Faulkner
New Biotechnology|September 25, 2016
Economic viability of Stratified Medicine concepts: An investor perspective on drivers and conditions that favour using Stratified Medicine approaches in a cost-contained healthcare environmentHans-Joerg Fugel, Mark Nuijten, Maarten Postma
BMC Health Services Research|October 10, 2014
An economic assessment of embryo diagnostics (Dx) - the costs of introducing non-invasive embryo diagnostics into IVF standard treatment practicesHans-Joerg Fugel, Mark Connolly, Mark Nuijten
Clinical Therapeutics|September 20, 2006
Patterns of dosage changes with transdermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: a retrospective data analysis in GermanyReinhard Sittl, Mark Nuijten, Barbara Poulsen Nautrup
Frontiers in Pharmacology|October 23, 2012
Stratified medicine and reimbursement issuesHans-Joerg Fugel, Mark Nuijten, Maarten Postma
Clinical Therapeutics|September 13, 2005
Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort studyReinhard Sittl, Mark Nuijten, Barbara Poulsen Nautrup
Pharmacoeconomics|March 22, 2021
Replication of Published Health Economic Obesity Models: Assessment of Facilitators, Hurdles and Reproduction SuccessBjörn Schwander, Mark Nuijten, Silvia Evers, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
Clinicoeconomics and Outcomes Research : CEOR|December 19, 2013
Health economic evidence of 5% lidocaine medicated plaster in post-herpetic neuralgiaHiltrud Liedgens, Marko Obradovic, Mark Nuijten
Clinical Drug Investigation|January 14, 2010
Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysisMark Ritchie, Hiltrud Liedgens, Mark Nuijten
Journal of Medical Economics|October 9, 2009
Cost effectiveness of palivizumab for RSV prevention in high-risk children in the NetherlandsMark Nuijten, Maximilian Lebmeier, Wolfgang Wittenberg
Journal of Medical Economics|March 25, 2014
The application of economics concepts to stratified medicine--use of health economics data to support market access for stratified medicine interventionsHans-Joerg Fugel, Mark Nuijten, Eric Faulkner
New Biotechnology|September 25, 2016
Economic viability of Stratified Medicine concepts: An investor perspective on drivers and conditions that favour using Stratified Medicine approaches in a cost-contained healthcare environmentHans-Joerg Fugel, Mark Nuijten, Maarten Postma
BMC Health Services Research|October 10, 2014
An economic assessment of embryo diagnostics (Dx) - the costs of introducing non-invasive embryo diagnostics into IVF standard treatment practicesHans-Joerg Fugel, Mark Connolly, Mark Nuijten
Clinical Therapeutics|September 20, 2006
Patterns of dosage changes with transdermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: a retrospective data analysis in GermanyReinhard Sittl, Mark Nuijten, Barbara Poulsen Nautrup
Frontiers in Pharmacology|October 23, 2012
Stratified medicine and reimbursement issuesHans-Joerg Fugel, Mark Nuijten, Maarten Postma
Clinical Therapeutics|September 13, 2005
Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort studyReinhard Sittl, Mark Nuijten, Barbara Poulsen Nautrup
Pharmacoeconomics|March 22, 2021
Replication of Published Health Economic Obesity Models: Assessment of Facilitators, Hurdles and Reproduction SuccessBjörn Schwander, Mark Nuijten, Silvia Evers, et al.
Pageof 4